Intravitreal aflibercept injections improve VA in patients with myopic CNV
Intravitreal aflibercept injections in patients with myopic choroidal neovascularization (CNV) resulted in long-term improvement in visual acuity, according to a study.
Primary intravitreal aflibercept injections were administered to 21 treatment-naive eyes (21 patients) patients with subfoveal/juxtafoveal myopic CNV. Patients were followed for at least 12 months.
There was a significant improvement in mean best-corrected visual acuity (BCVA) from baseline to 12 months after treatment (0.7 to 0.3 logMAR). Compared to patients ≥50 years old, the median BCVA improvements after treatments at 3 and 12 months were not statistically significant in patients <50 years old.
Overall, 47.6% of patients had CNV resolved after 1 aflibercept injection.
In the patients <50 years old, a greater improvement in the median central foveal thickness was seen compared to the older group.
In 12 patients with myopic CNV, optical coherence tomography angiography identified an interlacing pattern of the outer retinal layer. In these patients, a trend in anatomical improvement after the injection.
Chen SL, Tang PL, Wu TT. Result of intravitreal aflibercept injection for myopic choroidal neovascularization. BMC Ophthalmol. 2021 Sep 22;21(1):342. doi: 10.1186/s12886-021-02088-x. PMID: 34551746.